Hims & Hers Health, Inc. (HIMS)
NYSE:HIMS
Want to see HIMS full AI Analyst Report?
HIMS Stock Chart & Stats
$25.05
-$0.61(-2.20%)
At close: 4:00 PM EST
$25.05
-$0.61(-2.20%)
Day’s Range― - ―
52-Week Range$13.74 - $70.43
Previous CloseN/A
Volume4.28M
Average Volume (3M)22.67M
Market Cap
$8.21B
Enterprise Value$8.02B
Total Cash (Recent Filing)$750.88M
Total Debt (Recent Filing)$1.13B
Price to Earnings (P/E)―
Beta2.57
Next Earnings
Aug 10, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding223,080,080
10 Day Avg. Volume20,707,089
30 Day Avg. Volume22,671,812
Financial Highlights & Ratios
PEG Ratio-33.04
Price to Book (P/B)13.50
Price to Sales (P/S)3.11
P/FCF Ratio98.76
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue3.39
Enterprise Value/Gross Profit5.01
Enterprise Value/Ebitda266.95
Forecast
1Y Price Target
$28.32Price Target Upside13.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$2.89B
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Upgraded GuidanceManagement raised full-year 2026 revenue guidance and TTM revenue is up ~94%, indicating durable top-line momentum. Sustained subscription growth and category expansion (weight-loss, international) should expand recurring revenue and support longer-term scale economics and predictable cash generation.
Strong Cash GenerationConsistent positive operating and free cash flow provides self-funding for growth initiatives, reduces reliance on external capital, and supports investments in tech, labs, and international expansion. Durable cash conversion improves runway for scaling while absorbing strategic investments.
Global Platform ExpansionClosing Eucalyptus materially broadens Hims & Hers' addressable market and regulatory footprint, creating local operating scale, data network effects and cross-market product rollouts. That structural expansion can deliver multi-market revenue diversification and long-term operational leverage.
Bears Say
Elevated Leverage & FinancingLeverage rising to ~2.5x and recent convertible-note issuance increase refinancing and covenant risk and reduce financial flexibility. Higher debt levels constrain discretionary spending, raise stress from margin shocks, and can force capital decisions that dilute shareholders or limit optionality over the medium term.
Margin Pressure From Strategic PivotA structural shift into lower-margin specialties (branded weight-loss, labs, international) and cadence changes can permanently compress gross margins. Lower unit economics make profitability more sensitive to marketing and supply costs, limiting margin sustainability unless offset by price or efficiency gains.
Profitability VolatilityTransition from prior profitability to a TTM net loss highlights earnings volatility tied to restructuring, M&A and transient supply issues. Persistent GAAP losses increase the importance of cash flow conversion and operating leverage to achieve durable profitability and absorb future investments.
Hims & Hers Health News
HIMS FAQ
What was Hims & Hers Health, Inc.’s price range in the past 12 months?
Hims & Hers Health, Inc. lowest stock price was $13.74 and its highest was $70.43 in the past 12 months.
What is Hims & Hers Health, Inc.’s market cap?
Hims & Hers Health, Inc.’s market cap is $8.21B.
When is Hims & Hers Health, Inc.’s upcoming earnings report date?
Hims & Hers Health, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 49 days.
How were Hims & Hers Health, Inc.’s earnings last quarter?
Hims & Hers Health, Inc. released its earnings results on May 11, 2026. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of $0.025 by -$0.425.
Is Hims & Hers Health, Inc. overvalued?
According to Wall Street analysts Hims & Hers Health, Inc.’s price is currently Undervalued.
Does Hims & Hers Health, Inc. pay dividends?
Hims & Hers Health, Inc. does not currently pay dividends.
What is Hims & Hers Health, Inc.’s EPS estimate?
Hims & Hers Health, Inc.’s EPS estimate is -0.05.
How many shares outstanding does Hims & Hers Health, Inc. have?
Hims & Hers Health, Inc. has 223,080,080 shares outstanding.
What happened to Hims & Hers Health, Inc.’s price movement after its last earnings report?
Hims & Hers Health, Inc. reported an EPS of -$0.4 in its last earnings report, missing expectations of $0.025. Following the earnings report the stock price went up 3.077%.
Which hedge fund is a major shareholder of Hims & Hers Health, Inc.?
Currently, no hedge funds are holding shares in HIMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hims & Hers Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.32 (13.05% Upside)
$28.32 (13.05% Upside)
Blogger Sentiment
Bullish
HIMS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.91%
12-Months-Change
Fundamentals
Return on Equity
-2.48%
Trailing 12-Months
Asset Growth
154.24%
Trailing 12-Months
Company Description
Hims & Hers Health, Inc.
Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.
HIMS Company Deck
HIMS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of near-term headwinds tied to a deliberate strategic pivot (one-time restructuring charges, gross-margin pressure, GAAP loss and short-term volatility) alongside several strong growth signals: raised full-year revenue guide, rapid adoption of branded GLP-1 products (125k+ Wegovy shipments in six weeks and on track for >100k monthly subscribers), international revenue growth (~10x to $78M), positive operating cash flow ($89M) and deep investments in AI, labs and verticalized supply chain. Management expects accelerating EBITDA in H2 as monthly cohorts compound and efficiencies emerge. Given the substantial operational and commercial progress and the forward-looking guidance offsetting temporary accounting and margin noise, the positive operational momentum and upgraded outlook outweigh the short-term financial disruptions.View all HIMS earnings summariesHIMS Revenue Breakdown
96.60% Online
3.40% Wholesale
HIMS Stock 12 Month Forecast
Average Price Target
$28.32
▲(13.05% Upside)
Technical Analysis
Ownership Overview
5.22% Insiders
14.51% Mutual Funds
12.73% Other Institutional Investors
47.58% Public Companies and Individual Investors